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Abstract
Loss of phosphatase and tensin homologue (PTEN) expression may be prog-
nostic in colorectal cancer (CRC) and may have a correlation with vascular
endothelial growth factor (VEGF) expression via hypoxia-inducible factor 1
(HIF-1) alpha, and the PI3K/mTOR pathways. We therefore have explored the
prognostic association of PTEN loss and the potential that PTEN loss may be
predictive of outcome with bevacizumab. Patients enrolled in the AGITG
MAX trial, a randomized Phase III trial of capecitabine (C) +/ bevacizumab
(B) (+/ mitomycin C [M]) with available tissues were analyzed for PTEN
expression (loss vs. no loss) as assessed using a Taqman copy number assay
(CNA). Of the original 471 patients enrolled, tissues from 302 (64.1%) patients
were analyzed. PTEN loss was observed in 38.7% of patients. There was no
relationship between PTEN loss and KRAS or BRAF mutation. PTEN status
was not prognostic for progression-free survival (PFS) or overall survival (OS)
in multivariate analyses adjusting for other baseline factors; loss versus no loss
PFS hazard ratio (HR) 0.9 (0.7–1.16), OS HR 1.04 (0.79–1.38). PTEN was not
prognostic when assessed by KRAS and BRAF status. By using the comparison
of C versus CB+CBM, PTEN status was not significantly predictive of the effec-
tiveness of B for PFS or OS. PTEN status was not prognostic for survival in
advanced colorectal cancer, irrespective of KRAS or BRAF status. PTEN status
did not significantly predict different benefit with bevacizumb therapy.
Introduction
Treatment of cancer as a whole has evolved over recent
years with the development of so called targeted therapies
based on our greater understanding of molecular path-
ways in cancer. For colorectal cancer (CRC) the major
advances have involved drugs that target the epidermal
growth factor receptor (EGFR) and vascular endothelial
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growth factor (VEGF) [1]. As only a subset of patients
derives benefit from targeted agents, a major focus of cur-
rent research is the search for biomarkers which may pre-
dict patients who may have greater degrees of sensitivity
to a particular targeted agent. For anti-EGFR monoclonal
antibodies, the accepted predictors include KRAS [2, 3]
and potentially BRAF [4]. There remains, however, an
urgent need for biomarkers for anti-VEGF therapies.
The tumor suppressor gene PTEN (phosphatase and
tensin homologue deleted on chromosome 10) is an
important negative regulator of the PI3K/AKT pathway
and controls cell proliferation, survival, and angiogenesis.
In patients with metastatic colorectal cancer (mCRC),
PTEN gene mutation has been reported in 2–20%, with
higher rates in microsatellite stable groups [5], while loss
of PTEN protein has been reported in 13–55% [6–10].
There is debate as to the best method of reporting low
PTEN expression/loss of function, with the most frequent
method reported being immunohistochemistry (IHC) [4],
although more recently copy number alterations (CNA)
in PTEN have been used to assess prognosis in prostate
cancer [11]. Furthermore, recent reports have complicated
matters further by differentiating roles of cytoplasmic and
nuclear PTEN [12]. The prognostic value of PTEN loss in
mCRC also remains controversial. Results have thus far
been based on small patient numbers, mostly involving
patients receiving anti-EGFR antibodies, and have been
somewhat inconsistent. Laurent-Puig et al. [13] found
that loss of PTEN expression was associated with poorer
OS in a KRAS wild-type (WT) population, who had
received cetuximab plus or minus irinotecan. A further
analysis of primarily Stage II and III CRC also suggested
loss of PTEN expression is associated with worse out-
come, but primarily in the Stage II group [14]. In con-
trast, Loupakis et al. [15] failed to confirm an association
of PTEN and outcome and, furthermore, showed that
PTEN status varies between primary and secondary tumor
samples, further complicating interpretation of the data.
PTEN is thought to have a potential role as a biomarker
for anti-EGFR therapy in CRC, although the results are
not consistent. Relevant to this patient group, there is evi-
dence that decreased levels of PTEN results in increased
expression of VEGF, suggesting a potential relationship of
outcomes and anti-VEGF therapy [16]. One suggested
mechanism is that PTEN loss results in unopposed PI3K
activity, which in turn may promote VEGF effects on
endothelial cells. This effect is particularly the case in
hypoxia where up regulation of hypoxia-inducible factor
1 (HIF-1) alpha by PI3K/mTOR activation results in
increased VEGF expression [17, 18].
Given the potential interaction between loss of PTEN
expression and VEGF pathway activation and importantly
the uncertainty in relation to its impact on prognosis, we
undertook an analysis of tumor samples collected during
the course of the AGITG MAX trial, which involved
patients with advanced colorectal cancer receiving chemo-
therapy with or without the anti-VEGF antibody bev-
acizumab. We aimed to evaluate the prognostic impact of
PTEN loss based on CNA, as well as determining the
potential for predictive outcomes in patients receiving
bevacizumab treatment. We also assessed the interaction
of PTEN loss and KRAS and BRAF status on prognosis
and outcome with bevacizumab.
Methods and Patients
Patients and study design
The MAX study design and eligibility criteria have been
reported previously [19]. The primary objective of this
Phase III study was to evaluate the effect of adding bev-
acizumab with or without mitomycin C to capecitabine
on progression-free survival (PFS) among patients receiv-
ing first line chemotherapy for their mCRC. Enrollment
occurred between July 2005 and June 2007. Patients were
randomly assigned to receive capecitabine (C), capecita-
bine and bevacizumab (CB), and capecitabine, bev-
acizumab, and mitomycin C (CBM). Patients were
evaluated for tumor response or progression every
6 weeks. Treatment was continued until the disease pro-
gressed or until the patient could not tolerate the toxic
effects. All patients participating in translational studies
provided written informed consent at the time of study
enrolment. Ethics approval for translational studies was
obtained centrally. To assess whether PTEN was predic-
tive of bevacizumab treatment efficacy, a proportional
hazards model with treatment covariate (C vs. CB and
CBM), PTEN expression, and their interaction was
assessed. To determine whether PTEN was an indepen-
dent prognostic factor, a multivariate proportional haz-
ards regression model was fitted to data for all patients,
with PTEN CNA and other trial protocol pre-specified
baseline covariates in the model.
Tumor collection and processing
Formalin-fixed, paraffin-embedded (FFPE) samples of
tumor tissue from archival specimens collected at the
time of diagnosis were retrieved from storage at hospital
pathology departments. Genomic DNA was isolated from
1 to 2 FFPE tissue sections (10 lm) from each case
mounted on a plain glass slide, with an adjacent section
stained with haematoxylin and eosin for reference. Cases
were reviewed by a histopathologist and if deemed to
have <50% malignant crypts in the section, the tissue was
manually dissected to ensure a high proportion of tumor
278 ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Analysis of PTEN CNA in Patients With Advanced Colorectal Cancer T. J. Price et al.
cells. Paraffin was removed by xylene and DNA extracted
using the QIAamp DNA FFPE tissue kit (Qiagen, Valen-
cia, CA), according to the manufacturer’s protocol.
Researchers who assessed PTEN copy number were
blinded from clinical endpoints. As per the protocol, loss
of PTEN is defined as  1.5 copies, no loss was >1.5
copies.
PTEN analyses
All available tissue samples were analyzed for PTEN copy
number as assessed using a Taqman copy number assay
(Life Technologies, Carlsbad, CA) to measure copy num-
ber variation at the PTEN locus. The assay is a duplex
polymerase chain reaction (PCR) for the PTEN gene and
the reference gene, RNaseP (normalizer), using 10 ng
DNA in quadruplicate PCR according to the supplier’s
protocol and run on the Rotorgene 6000 real time PCR
instrument (Qiagen). The results were calculated as a
ratio relative to a 2-copy control using the 2ΔΔCt method
(Rotorgene software), and multiplied by 2 to give the
copy number. Loss of PTEN was defined as 1.5 copies,
no loss was >1.5 copies. We tested DNA from colon can-
cer cell lines to determine the reproducibility of the assay
and to select cell lines (LIM2405, LIM1899, HT29) with
known PTEN copy number, to use as 1, 2, and 3 copy
controls, respectively. The controls were tested in quadru-
plicate and repeated in three separate PCR assays. The
assay was both precise and reproducible – the means for
the controls for 1 copy, 2 copies, and 3 copies were 1.08
SEM 0.04, 2.07 SEM 0.03, and 2.96 SEM 0.07, respec-
tively. The coefficient of variation (CV) between eight
runs was 2.4%, and intra-assay CV was between 0.12%
and 0.99%.
KRAS and BRAF analysis
The methods used for assessing KRAS and BRAF muta-
tions have been previously described [20].
Statistical analysis
All randomly assigned patients for whom data on PTEN
expression (loss vs. no loss) were available were included
in the analysis. PFS, the primary endpoint, was defined as
the time from randomization until documented evidence
of disease progression according to the Response Evalua-
tion Criteria in Solid Tumors (RECIST) version 1.0,
the occurrence of new disease or death from any cause.
The secondary endpoints were overall survival (OS),
defined as the time from randomization until death from
any cause; and response rate (RR), defined according to
RECIST version 1.0.
The PFS of patients according to PTEN expression and
treatment groups were summarized with the use of Kaplan–
Meier curves, and the difference between these groups
was compared (C vs. CB and CBM) with the use of the
log-rank test. A proportional hazards model with treat-
ment covariate (C vs. CB and CBM), PTEN expression,
and their interaction was used to assess whether PTEN
was predictive of bevacizumab treatment efficacy. To
assess whether PTEN was an independent prognostic fac-
tor, a multivariate proportional hazards regression model
was fitted to data for all patients, with PTEN expression
and other trial protocol pre-specified baseline covariates
in the model. The same methods were used for grouping
by KRAS and BRAF, based on the tissue population status
as previously published [20].
Results
Characteristics of the patients
Of 471 patients who underwent random assignment, a
total of 302 tumor specimens were examined for PTEN
expression (accounting for 64.1% of the total study popu-
lation; Fig. 1). Specimen breakdown is as follows: Arm A
(C) primary tumors 90, metastasis 4, Lymph node 3, Local
recurrence 1 (n = 98); Arm B (C+B) primary 100, metasta-
sis 4, Lymph node 3, Local recurrence 2 (n = 109); Arm C
(C+B+M) primary 92, metastasis 3 (n = 95). The median
follow-up time of these patients was 30.6 months (range,
0.4–42.4 months). Overall 94% of tissue assessed came
from the primary. Tumor specimens from the remaining
patients could not be retrieved or were not suitable for
analysis. Although a nominal figure of >50% malignant
crypts was required in each section as part of the original
design, to reduce the impact of normal tissue on the PTEN
analysis, minimal normal tissue was allowed and manual
dissection ultimately occurred in 70.5% of cases.
Among those patients analyzed for PTEN expression
(n = 302), PTEN loss was observed in 38.7%. Baseline
characteristics by PTEN expression are summarized in
Table 1. PTEN loss was more frequent in patients with
primary rectal cancer (P = 0.01), and patients were less
likely to have lung metastasis (P = 0.03). There was no
association between PTEN loss and KRAS mutation
(P = 0.24) or BRAF (P = 0.89) mutation. Other baseline
characteristics were similar between those with and with-
out loss of PTEN expression.
Baseline characteristics of those with and without tis-
sues for PTEN analysis were also comparable (Table 1);
clinical outcomes were comparable with no significant
difference in primary or secondary clinical outcomes
between the total study population and the patients who
were evaluated for PTEN expression (Tables S1 and S2).
ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 279
T. J. Price et al. Analysis of PTEN CNA in Patients With Advanced Colorectal Cancer
Progression-free survival
Among patients with loss of PTEN expression in tumors,
the median PFS was 6.0 months in the group receiving
capecitabine and was 9.2 months in the groups receiving
CB or CBM. The hazard ratio (HR) of disease progression
was 0.51 (95% CI, 0.33–0.79, P = 0.002; Fig. 2). Among
patients with no PTEN loss in tumors, the median PFS
was 6.1 months in the group receiving capecitabine and
was 8.4 months in the groups receiving CB or CBM (HR,
0.72; 95% CI, 0.52–0.98; P = 0.04; Fig. 2). The additional
benefit of bevacizumab on PFS was not significantly
greater among the patients with loss of PTEN expression
in tumors than among patients with no PTEN loss in
tumors (P = 0.26 for the interaction between PTEN
expression and the assigned treatment).
Overall survival
Among patients with loss of PTEN expression in tumors,
the median OS was 19.1 months in the group receiving
capecitabine and was 20.4 months in the groups receiving
CB or CBM (HR, 0.75; 95% CI, 0.47–1.19; P = 0.22).
Among patients with no PTEN loss in tumors, the med-
ian OS was 21.4 months in the group receiving capecita-
bine and was 18.4 months in the groups receiving CB or
CBM (HR, 1.00; 95% CI, 0.70–1.43; P = 0.99). The effect
of the addition of bevacizumab on OS was not signifi-
cantly greater among the patients with loss of PTEN
expression in tumors than among patients with no PTEN
loss in tumors (P = 0.35 for the interaction between
PTEN expression and the assigned treatment).
Response to treatment
RR that was based on PTEN expression is summarized in
Table 2. The effect of the addition of bevacizumab on
response was not significantly greater among the patients
with loss of PTEN expression in tumors than among
patients with no PTEN loss in tumors (P = 0.36 for the
interaction between PTEN expression and the assigned
treatment).
Prognostic value of PTEN
Regardless of treatment arms, PTEN expression did not
significantly impact on PFS. The median PFS was
8.6 months among patients with loss of PTEN expression
in tumors compared with 7.2 months for patients with
no PTEN loss in tumors (HR of PTEN loss vs. no loss,
0.90; 95% CI, 0.70–1.14; P = 0.38; Fig. 3A). Similarly,
there was no prognostic value noted for PTEN expression
on OS (Fig. 3B), with median OS of 19.8 months for
those with loss of PTEN expression in tumors compared
with 20.0 months for those with no PTEN loss in tumors
(HR of PTEN loss vs. no loss, 1.01; 95% CI 0.77–1.32,
P = 0.96).
In KRAS mutation patients, PTEN expression did not
significantly impact on PFS or OS (PFS: median PFS loss
vs. no loss, 7.7 vs. 7.4 months; P = 0.13; OS: median OS
loss vs. no loss, 20.3 vs. 18.4 months; P = 0.67). In KRAS
wild-type patients, PTEN expression also did not signifi-
cantly impact on PFS or OS (PFS: median PFS loss vs. no
loss, 8.8 vs. 7.2 months; P = 0.91; OS: median OS loss vs.
no loss, 19.6 vs. 21.1 months; P = 0.59).
Figure 1. CONSORT diagram. C, capecitabine; CB, capecitabine plus bevacizumab; CBM, CB plus mitomycin.
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BRAF mutation is prognostic for poorer OS (median
OS mutation vs. wild-type, 8.6 vs. 20.8 months;
P = 0.001; Fig. 3C). In BRAF mutation patients, PTEN
expression did not significantly impact on PFS or OS
(PFS: median PFS loss vs. no loss, 7.5 vs. 4.2 months;
P = 0.53; OS: median OS loss vs. no loss, 8.6 vs.
8.2 months; P = 0.91). In BRAF wild-type patients, PTEN
expression also did not significantly impact on PFS or OS
(PFS: median PFS loss vs. no loss, 8.9 vs. 7.5 months;
P = 0.40; OS: median OS loss vs. no loss, 20.4 vs.
21.4 months; P = 0.66).
Multivariate analyses to adjust for predefined baseline
clinico-pathologic prognostic factors did not change
these results for the prognostic significance of PTEN
expression on both PFS and OS outcomes (results not
shown).
Table 1. Baseline patient demographic characteristics.
All patients who
underwent
randomization
(n = 471) %
No PTEN loss
(n = 185) %
PTEN loss
(n = 117) % P-value
Age (years)
Median 67 67 69 0.06
Range 32–86 32–85 32–85
Male 295 63 120 65 68 58 0.24
ECOG performance status
0 263 56 112 61 66 56 0.44
1 178 38 65 35 42 36
2 30 6 8 4 9 8
Capecitabine dosage
1 g/m2 bd 314 67 116 63 83 71 0.14
1.25 g/m2 bd 157 33 69 37 34 29
Disease-free interval > 12 months 125 27 49 27 37 33 0.31
KRAS mutation1 90 29 55 29 28 24 0.24
KRAS wild-type1 224 71 127 70 89 76
BRAF mutation1 33 11 20 11 12 10 0.89
BRAF wild-type1 280 89 163 88 103 88
Prior adjuvant treatment
Chemotherapy 104 22 40 22 29 25 0.52
Radiotherapy 59 13 13 7 16 14 0.06
Primary site of cancer
Caecum 49 10 20 11 8 7 0.25
Ascending colon 47 10 30 16 11 9 0.09
Transverse colon 28 6 13 7 5 4 0.33
Descending colon 16 3 5 3 6 5 0.27
Sigmoid colon 139 30 52 28 39 33 0.34
Recto-sigmoid colon 54 11 26 14 11 9 0.23
Rectum 107 23 29 16 32 27 0.01
Other 27 6 9 5 5 4 0.81
Uncertain 4 1 1 1 0 0 0.43
Primary tumor resected 371 79 161 87 110 94 0.05
Any metastases resected 45 10 14 8 12 10 0.42
Extent of disease at baseline
Local disease (colon or rectum) 169 36 58 31 29 25 0.22
Liver metastases 353 75 131 71 91 78 0.18
Lymph node metastases 219 47 87 47 53 45 0.77
Lung metastases 185 39 64 35 55 47 0.03
Bone metastases 18 4 6 3 4 3 0.93
Peritoneal metastases 84 18 33 18 17 15 0.45
Other metastases 49 10 24 13 11 9 0.35
ECOG, Eastern Cooperative Oncology Group; PTEN, phosphatase and tensin homologue.
1Only 66.9% of the total patient population was evaluated for KRAS and BRAF mutations. Not all of these patients were also evaluated for PTEN
expression.
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Discussion
Results from the patients with tissue available for PTEN
analysis (64.1%) from the randomized Phase III MAX
trial show that PTEN status as measured by CNA did not
significantly predict differences in benefit from the anti-
VEGF agent bevacizumab. PTEN CNA therefore does not
appear to be a predictive factor for anti-VEGF therapy in
mCRC. Moreover, PTEN CNA was also not found to be
prognostic for survival in advanced colorectal cancer.
Loss of PTEN expression (or activity) has been previ-
ously assessed as a potential predictive biomarker for resis-
tance to EGFR-targeted monoclonal antibodies in patients
with mCRC [4, 21]. IHC is frequently used, although other
methods have also been reported (fluorescence in situ
hybridization (FISH), mutation status, and CNA) to
assess loss of PTEN expression/activity. The accurate
determination of PTEN status is difficult, and is not
always reliable, particularly when assessed by IHC given
the potential for inter reporter variation [22]. Assessment
of PTEN expression is further complicated by potential
discordance between the expression of PTEN in the pri-
mary and metastatic tissue. Concordance rates reported
vary from 47% to 89% between primary and secondary
Figure 2. Forest plot to demonstrate hazard ratios (HRs) for progression-free survival subgroup analyses by PTEN status. C, capecitabine; CB,
capecitabine plus bevacizumab; CBM, CB plus mitomycin; PTEN, phosphatase and tensin homologue.
Table 2. Response rate by PTEN expression.
Treatment PTEN loss (%) PTEN no loss (%) P1
C 35.5 34.3 0.36
CB 40.5 32.8
CBM 56.8 39.2
C, capecitabine; CB, capecitabine and bevacizumab; CBM, capecita-
bine, bevacizumab, and mitomycin; PTEN, phosphatase and tensin
homologue.
1P-value for interaction between biomarker status and the assigned
treatment (C vs. CB and CBM).
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tissue [22–25]. FISH may have a role with higher concor-
dance rates of 82% reported, although this study had only
8 patients [8]. Even if concordance rates are improved,
reliability is also complicated by the findings of Loupakis
et al. [15] who found that PTEN loss in the primary
tumor was not predictive of resistance to EGFR-targeted
monoclonal antibodies, but it was predictive in metastatic
tissue. Newer methods using a Taqman copy number
assay to measure CNA at the PTEN locus in a duplex
PCR as used in our study may allow for more reproduc-
ible results. There remains a need to compare the various
methods assessing PTEN loss, although given the
described variations in IHC PTEN assessment it will be
difficult to define what is a standardized approach.
In our study, 94% of tissue was from the primary,
which may have reduced the impact of tissue source vari-
ation and thus allow for more consistent results,
although it did not allow us to assess the effect of PTEN
loss in metastases on prognosis. Ultimately however, the
issues of interpreter variation for IHC and low concor-
dance between primary and metastasis may make routine
interpretation of PTEN status difficult in clinical practice
and repeat biopsy of new lesions may be required if
PTEN is to be used as a robust predictive marker in this
setting.
Assessing PTEN status in the setting of anti-VEGF ther-
apy is based on the proposed interaction of the PI3K/
PTEN/AKT pathway and VEGF expression [16–18, 26].
Activation of AKT, in part induced by over expression of
VEGF itself, leads to angiogenesis [27] and PTEN loss
facilitates PI3K expression. HIF-1 (a and b) is also a
potent stimulus of VEGF production and although
hypoxia itself is a key factor, activation of VEGF poten-
tially via PI3K can also contribute to increased HIF-1a
[17]. Anti-VEGF therapy may therefore overcome to a
degree these driving factors. Thus one may hypothesize
that the addition of bevacizumab may be more effective
in patients with low or no expression of PTEN. However,
our study has shown that PTEN loss does not appear to
affect bevacizumab efficacy based on PFS, RR, or OS.
Thus PTEN copy number loss is not a predictive factor
for bevacizumab therapy when combined with capecita-
bine in metastatic CRC.
Prognostically, PTEN loss, with its subsequent down-
stream effect on the PI3K/AKT pathway, may impact on
outcome given the stimulation of tumorigenesis [26], as
well as angiogenesis. Prior reports on the effect of PTEN
on prognosis have been variable [6, 7]. For example Lau-
rent-Puig et al. [13] primarily report on the KRAS WT
group receiving cetuximab rather than the whole popula-
tion. Although in this specific group they found loss of
PTEN associated with poor OS, we also assessed this sub-
group and failed to confirm this result in a patient popu-
lation not receiving an anti-EGFR agent. This suggests
that their findings may relate more to the impact of
PTEN on predicting outcomes to anti-EGFR agents. Hsu
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mutated; WT, wild type; PTEN, phosphatase and tensin homologue.
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et al. [14] also studied PTEN loss predominantly in early
stage disease (Stage II and III) and suggested a prognostic
effect but, primarily in the Stage II population. This has
also been reported when assessing the relationship of
KRAS status and prognosis with conflicting results and
differences based on stage noted. For example, the RAS-
CAL cooperative was for all stages of colorectal cancer
and 12 possible mutations on codons 12 and 13 of KRAS
were assessed [28]. Only one mutation on codon 12, gly-
cine to valine, found in 8.6% of all patients, had a statis-
tically significant impact on PFS (P = 0.004, HR 1.3) and
OS (P = 0.008, HR 1.29) and the impact on outcome
appeared to be greater in Dukes’ C cancers (PFS, P = 0.008,
HR 1.5; OS P = 0.02, HR 1.45) rather than in Dukes’ B
tumors (PFS, P = 0.46, HR 1.12; OS P = 0.36, HR 1.15)
and there was no obvious signal in mCRC. Ultimately our
results from a large dataset of patients with metastatic dis-
ease do not support loss of PTEN expression based on
CNA as a prognostic marker in the overall population or
any subgroups based on KRAS or BRAF mutation status.
In conclusion, PTEN CNA cannot be considered a pre-
dictive factor for anti-VEGF therapy with bevacizumab,
or a prognostic factor for mCRC. There remains a need
to further explore potential markers of outcome for anti-
VEGF therapy to better select patients best treated with
this class of drug and additional studies are being under-
taken on the MAX study tissue population with this aim.
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